ArticlePloS one2013
RBP2 induces epithelial-mesenchymal transition in non-small cell lung cancer.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Roles of KDM5 demethylases in therapeutic resistance of cancers.Epigenetics & chromatin · 2025Review
- Review
- A prognostic model of non small cell lung cancer based on TCGA and ImmPort databases.Scientific reports · 2022Article
- Analysis of the tumor immune environment identifies an immune gene set-based prognostic signature in non-small cell lung cancer.Annals of translational medicine · 2022Article
- Poly(ADP-ribose) binding and macroH2A mediate recruitment and functions of KDM5A at DNA lesions.The Journal of cell biology · 2021Article
- The emerging role of KDM5A in human cancer.Journal of hematology & oncology · 2021Review
- Metformin Reduces Histone H3K4me3 at the Promoter Regions of Positive Cell Cycle Regulatory Genes in Lung Cancer Cells.Cancers · 2021Article
- A UHPLC-MS/MS method for the quantification of JIB-04 in rat plasma: Development, validation and application to pharmacokinetics study.Journal of pharmaceutical and biomedical analysis · 2020Article
- Novel immune subtypes of lung adenocarcinoma identified through bioinformatic analysis.FEBS open bio · 2020Article
- Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview.Expert opinion on therapeutic targets · 2019Review
- Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A.Journal of medicinal chemistry · 2018Article
- Inhibitors of Protein Methyltransferases and Demethylases.Chemical reviews · 2018Review
- A new semi-supervised learning model combined with Cox and SP-AFT models in cancer survival analysis.Scientific reports · 2017Article
- Allosteric regulation of epigenetic modifying enzymes.Current opinion in chemical biology · 2017Review
- Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.Oncotarget · 2016Article
- RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma.Experimental & molecular medicine · 2016Article
- siRNA targeting RBP2 inhibits expression, proliferation, tumorigenicity and invasion in thyroid carcinoma cells.Oncology letters · 2015Article
- Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism.Nature communications · 2015Article
- Retinoblastoma binding protein 2 (RBP2) promotes HIF-1α-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RBP2 has been found to actively participate in cancer progression. It inhibits the senescence of cancer cells, mediates cancer cell proliferation and promotes cancer metastasis. It is also essential to drug tolerance. However, the effects of RBP2 on epithelial-mesenchymal transition are still unknown. In this study, we analyzed the effects of RBP2 on epithelial-mesenchymal transition in non-small cell lung cancer. The results showed that RBP2 down-regulated the expression of E-cadherin by inhibiting the promoter activity of E-cadherin and up-regulated the expression of N-cadherin and snail via the activation of Akt signaling, and the overexpression of RBP2 induced epithelial-mesenchymal transition in non-small cell lung cancer cells. Our study further indicated that RBP2 may be a potential target for anti-lung cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.